Post-acute Sequelae of COVID-19 Among Solid Organ Transplant Recipients: Insights From the Omicron Period.

IF 1.9 Q3 TRANSPLANTATION

Transplantation Direct Pub Date : 2024-08-08 eCollection Date: 2024-09-01 DOI:10.1097/TXD.0000000000001690

Leela Morená, Ayman Al Jurdi, Christopher El Mouhayyar, Rucháma Verhoeff, Nora Alzahrani, Camille N Kotton, Leonardo V Riella

{"title":"Post-acute Sequelae of COVID-19 Among Solid Organ Transplant Recipients: Insights From the Omicron Period.","authors":"Leela Morená, Ayman Al Jurdi, Christopher El Mouhayyar, Rucháma Verhoeff, Nora Alzahrani, Camille N Kotton, Leonardo V Riella","doi":"10.1097/TXD.0000000000001690","DOIUrl":null,"url":null,"abstract":"Background: In solid organ transplant recipients (SOTRs), studies investigating post-acute sequelae of SARS-CoV-2 infection (PASC) are limited, and risk factors for their development require further investigation.Methods: In this cross-sectional study, we evaluated PASC symptoms among SOTRs followed at our institutions who had COVID-19 during the Omicron period from December 28, 2021, to November 4, 2022. Participants were surveyed using a newly published PASC score containing 13 symptoms experienced for ≥30 d. PASC was defined as a score of ≥12.Results: Of 299 SOTRs invited, 93 completed the survey and were analyzed. The mean age was 58 y and 43% were women. Forty-six individuals (49%) reported experiencing ≥1 PASC symptom for ≥30 d, of whom 13 (14%) met the PASC definition. Multivariable analysis showed that female sex (adjusted odds ratio [aOR] = 0.32; 95% confidence interval [CI], 0.12-0.83), years from transplantation (aOR = 0.90 per additional year; 95% CI, 0.81-0.99), and tixagevimab-cilgavimab preexposure prophylaxis (aOR = 0.33; 95% CI, 0.12-0.84) were associated with significantly lower odds of developing ≥1 PASC symptom.Conclusions: PASC symptoms are common in SOTRs infected during the Omicron period. PASC symptoms are less frequent in those with a longer time since transplant and in those who received tixagevimab-cilgavimab. New SARS-CoV-2 prevention and treatment strategies should also evaluate PASC symptoms as outcomes.","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 9","pages":"e1690"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11315561/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Direct","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/TXD.0000000000001690","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"TRANSPLANTATION","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In solid organ transplant recipients (SOTRs), studies investigating post-acute sequelae of SARS-CoV-2 infection (PASC) are limited, and risk factors for their development require further investigation.

Methods: In this cross-sectional study, we evaluated PASC symptoms among SOTRs followed at our institutions who had COVID-19 during the Omicron period from December 28, 2021, to November 4, 2022. Participants were surveyed using a newly published PASC score containing 13 symptoms experienced for ≥30 d. PASC was defined as a score of ≥12.

Results: Of 299 SOTRs invited, 93 completed the survey and were analyzed. The mean age was 58 y and 43% were women. Forty-six individuals (49%) reported experiencing ≥1 PASC symptom for ≥30 d, of whom 13 (14%) met the PASC definition. Multivariable analysis showed that female sex (adjusted odds ratio [aOR] = 0.32; 95% confidence interval [CI], 0.12-0.83), years from transplantation (aOR = 0.90 per additional year; 95% CI, 0.81-0.99), and tixagevimab-cilgavimab preexposure prophylaxis (aOR = 0.33; 95% CI, 0.12-0.84) were associated with significantly lower odds of developing ≥1 PASC symptom.

Conclusions: PASC symptoms are common in SOTRs infected during the Omicron period. PASC symptoms are less frequent in those with a longer time since transplant and in those who received tixagevimab-cilgavimab. New SARS-CoV-2 prevention and treatment strategies should also evaluate PASC symptoms as outcomes.

查看原文本刊更多论文

COVID-19在实体器官移植受者中的急性后遗症：欧米茄时期的启示

背景：在实体器官移植受者（SOTRs）中，有关 SARS-CoV-2 感染后急性后遗症（PASC）的研究十分有限，需要进一步研究其发生的风险因素：在实体器官移植受者（SOTRs）中，调查 SARS-CoV-2 感染急性后遗症（PASC）的研究非常有限，其发生的风险因素需要进一步调查：在这项横断面研究中，我们评估了在 2021 年 12 月 28 日至 2022 年 11 月 4 日的 Omicron 期间接受过 COVID-19 治疗并在本机构接受随访的 SOTR 的 PASC 症状。我们使用新公布的 PASC 评分对参与者进行了调查，该评分包含 13 种症状，持续时间≥30 d：在受邀的 299 名 SOTR 中，有 93 人完成了调查并接受了分析。平均年龄为 58 岁，43% 为女性。46人（49%）报告说，≥1个PASC症状持续≥30天，其中13人（14%）符合PASC定义。多变量分析显示，女性性别（调整后比值比 [aOR] = 0.32；95% 置信区间 [CI]，0.12-0.83）、移植后年数（aOR = 每增加一年 0.90；95% CI，0.81-0.99）和 tixagevimab-cilgavimab 暴露前预防（aOR = 0.33；95% CI，0.12-0.84）与出现≥1 种 PASC 症状的几率显著降低有关：结论：PASC 症状在 Omicron 期间感染的 SOTRs 中很常见。结论：在奥米克隆时期感染的 SOTRs 中，PASC 症状很常见。移植后时间较长的患者和接受过 tixagevimab-cilgavimab 治疗的患者出现 PASC 症状的频率较低。新的 SARS-CoV-2 预防和治疗策略也应将 PASC 症状作为评估结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation Direct TRANSPLANTATION-

CiteScore

3.40

自引率

4.30%

发文量

193

审稿时长

8 weeks